Summary
A new vasodilator drug, pinacidil, N″-cyano-N-4-pyridyl-N′-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension. Four patients received pinacidil monotherapy, and in 11 patients it was used with a diuretic or a beta-blocker. In all but one patient normotension was achieved with a mean daily pinacidil dose of 46.7 mg b.i.d. (range 20–100 mg). Side effects were few and were action-related. There was no evidence of early toxicity. Pinacidil is a promising new antihypertensive vasodilator, which deserves further clinical evaluation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arrigoni-Martelli E, Kaergaard Nielsen C, Bang Olsen U, Petersen HJ (1980) N″-Cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, monohydrate (P1134): A new, potent vasodilator. Experientia 36: 445–447
Kardel T, Hilden T, Carlsen J, Trap-Jensen J (1981) N″-Cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, a new vasodilating agent: acute effect on blood pressure and pharmacokinetics in hypertensive patients. J Cardiovasc Pharmacol 3: 1002–1007
Ramsay LE, Freestone S (1983) Preliminary evaluation of pinacidil in hypertension. Br J Clin Pharmacol 16: 336–338
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koliopoulos, K., Papadoyannis, D.E. & Karatzas, N.B. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. Eur J Clin Pharmacol 27, 287–289 (1984). https://doi.org/10.1007/BF00542161
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542161